Abstract: Systems and methods for subject clinical condition evaluation using a plurality of modules are provided. Modules comprise features whose corresponding feature values associate with an absence, presence or stage of phenotypes associated with the clinical condition. A first dataset is obtained having feature values, acquired through a first technical background from respective subjects in transcriptomic, proteomic, or metabolomic form, for at least a first of the plurality of modules. A second training dataset is obtained having feature values, acquired through a technical background other than the first technical background, from training subjects of the second dataset, in the same form as for the first dataset, of at least the first module. Inter-dataset batch effects are removed by co-normalizing feature values across the training datasets, thereby calculating co-normalized feature values used to train a classifier for clinical condition evaluation of the test subject.

Abstract: Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.

Abstract: Methods for diagnosis of sepsis are disclosed. In particular, the invention relates to the use of bio -markers for aiding diagnosis, prognosis, and treatment of sepsis, and to a panel of biomarkers that can be used to distinguish sepsis from noninfectious sources of inflammation, such as caused by traumatic injury, surgery, autoimmune disease, thrombosis, or systemic inflammatory response syndrome (SIRS).

Abstract: This disclosure provides a gene expression-based method for determining whether a subject having sepsis has an Inflammopathic phenotype, an Adaptive phenotype or a Coagulopathic phenotype. A kit for performing the method is also provided.

Abstract: Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.

Abstract: This disclosure provides a gene expression-based method for determining whether a subject having sepsis has an Inflammopathic phenotype, an Adaptive phenotype or a Coagulopathic phenotype. A kit for performing the method is also provided.

Abstract: Methods for diagnosis of bacterial and viral infections are disclosed. In particular, the invention relates to the use of biomarkers that can determine whether a patient with acute inflammation has a bacterial or viral infection.

Abstract: This disclosure provides a gene expression-based method for determining whether a subject has a viral infection or a bacterial infection. A kit for performing the method is also provided.

Abstract: Methods for diagnosis of bacterial and viral infections are disclosed. In particular, the invention relates to the use of biomarkers that can determine whether a patient with acute inflammation has a bacterial or viral infection.

Abstract: Methods for diagnosis of tuberculosis are disclosed. In particular, the invention relates to the use of a panel of biomarkers for aiding diagnosis, prognosis, and treatment of tuberculosis. The identified biomarkers can be used to detect active tuberculosis as well as to distinguish active tuberculosis from latent tuberculosis and other pulmonary and infectious diseases, and for monitoring responses to treatment.

Abstract: A method for estimating a diagnostic score includes adding a first aliquot of a test sample to a first reaction vessel, and a second aliquot of the test sample to a second reaction vessel. The test sample includes a first target nucleic acid and a second target nucleic acid. The second target nucleic acid has a lower expected abundance than the first target nucleic acid. The second aliquot has a larger volume than the first aliquot. A first relative abundance value of the first target nucleic acid and a second relative abundance value of the second target nucleic acid are estimated by performing a first real-time quantitative isothermal amplification assay in the first reaction vessel, and performing a second real-time quantitative isothermal amplification assay in the second reaction vessel, respectively. The diagnostic score is estimated based on the first relative abundance value and the second relative abundance value.

Abstract: Methods for diagnosis of tuberculosis are disclosed. In particular, the invention relates to the use of a panel of biomarkers for aiding diagnosis, prognosis, and treatment of tuberculosis. The identified biomarkers can be used to detect active tuberculosis as well as to distinguish active tuberculosis from latent tuberculosis and other pulmonary and infectious diseases, and for monitoring responses to treatment.

Abstract: Systems and methods for subject clinical condition evaluation using a plurality of modules are provided. Modules comprise features whose corresponding feature values associate with an absence, presence or stage of phenotypes associated with the clinical condition. A first dataset is obtained having feature values, acquired through a first technical background from respective subjects in transcriptomic, proteomic, or metabolomic form, for at least a first of the plurality of modules. A second training dataset is obtained having feature values, acquired through a technical background other than the first technical background, from training subjects of the second dataset, in the same form as for the first dataset, of at least the first module. Inter-dataset batch effects are removed by co-normalizing feature values across the training datasets, thereby calculating co-normalized feature values used to train a classifier for clinical condition evaluation of the test subject.

Abstract: Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.

Abstract: Methods for diagnosis of sepsis are disclosed. In particular, the invention relates to the use of biomarkers for aiding diagnosis, prognosis, and treatment of sepsis, and to a panel of biomarkers that can be used to distinguish sepsis from noninfectious sources of inflammation, such as caused by traumatic injury, surgery, autoimmune disease, thrombosis, or systemic inflammatory response syndrome (SIRS).

Abstract: Methods for diagnosis of sepsis are disclosed. In particular, the invention relates to the use of biomarkers for aiding diagnosis, prognosis, and treatment of sepsis, and to a panel of biomarkers that can be used to distinguish sepsis from noninfectious sources of inflammation, such as caused by traumatic injury, surgery, autoimmune disease, thrombosis, or systemic inflammatory response syndrome (SIRS).

Abstract: Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.

Abstract: Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.

Abstract: Methods for diagnosis of bacterial and viral infections are disclosed. In particular, the invention relates to the use of biomarkers that can determine whether a patient with acute inflammation has a bacterial or viral infection.

Abstract: Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.